首页|期刊导航|广东医学|扶正解毒颗粒经p38MAPK信号通路保护脓毒症大鼠心肌细胞的机制探究

扶正解毒颗粒经p38MAPK信号通路保护脓毒症大鼠心肌细胞的机制探究OA

Protective mechanism of Fuzheng Jiedu Granules on cardiomyocytes in septic rats through the p38MAPK signa-ling pathway

中文摘要英文摘要

目的 探讨扶正解毒颗粒(FZJG)对脓毒症大鼠心肌细胞的保护作用.方法 体外实验中,以脂多糖(LPS)诱导的H9c2心肌细胞为模型,采用CCK-8法确定FZJG安全浓度,检测其对活性氧(ROS)、炎症因子及凋亡相关基因表达的影响,并与p38MAPK抑制剂SB203580联合进行机制验证.体内实验中,采用盲肠结扎穿孔术(CLP)建立脓毒症心肌损伤(SIC)大鼠模型,随机分为空白组、模型组、FZJG低、中、高剂量组、阳性药(左西孟旦)组及FZJG高剂量+SB203580组,通过HE染色、血清心肌标志物、氧化应激指标、TUNEL凋亡检测、qRT-PCR及 Western blot等方法,综合评价FZJG的心肌保护作用及对p38MAPK通路的影响.结果 在体外实验中,CCK-8结果显示FZJG≤40 000 μg/mL时,细胞活力在95%以上,综合考虑实验安全性与有效性,最终确定选择10 000 μg/mL作为后续干预实验的最佳给药浓度.实验证明FZJG可显著降低 LPS 诱导的 H9c2 细胞 ROS 水平,下调 IL-6、IL-1β、TNF-α、Bax、Caspase-3 mRNA 表达,上调 Bcl-2 mRNA表达,且与SB203580联用效果更佳(P<0.05).体内实验表明,FZJG中、高剂量可显著降低SIC大鼠血清肌酸激酶同工酶MB(CK-MB)、乳酸脱氢酶(LDH)、肌钙蛋白I(cTnI)水平,减轻心肌病理损伤,下调炎症因子表达,改善氧化应激状态(提高SOD、GSH,降低MDA),抑制心肌细胞凋亡,并下调心肌组织p38MAPK mRNA表达及其蛋白磷酸化水平(P<0.05),与SB203580联合应用呈现协同保护效应.结论 FZJG对脓毒症诱导的心肌损伤具有明确的保护作用,其机制可能与抑制p38MAPK信号通路活化,进而减轻炎症反应、氧化应激及心肌细胞凋亡有关.该研究为将FZJG开发为治疗SIC的潜在多途径干预的中药复方提供了实验依据.

Objective To investigate the protective effects of Fuzheng Jiedu Granules(FZJG)on cardiomyocytes in sepsis and to elucidate the underlying mechanism involving the p38 mitogen-activated protein kinase(p38MAPK)sig-naling pathway.Methods In the in vitro study,an inflammatory injury model was established by stimulating H9c2 car-diomyocytes with lipopolysaccharide(LPS).The safe concentration of FZJG was determined using the Cell Counting Kit-8(CCK-8)assay.Intracellular reactive oxygen species(ROS)production,inflammatory cytokine expression,and ap-optosis-related gene expression were evaluated following FZJG treatment.The p38MAPK inhibitor SB203580 was used in combination with FZJG to verify the underlying mechanism.In the in vivo study,a rat model of sepsis-induced cardiomy-opathy(SIC)was established by cecal ligation and puncture(CLP).Animals were randomly assigned to the control group,model group,low-,medium-,and high-dose FZJG groups,positive control group(levosimendan),and high-dose FZJG plus SB203580 group.Myocardial protective effects and modulation of the p38MAPK pathway were comprehen-sively evaluated by hematoxylin-eosin(HE)staining,measurement of serum myocardial injury biomarkers,oxidative stress indices,terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling(TUNEL)assay,quantitative real-time polymerase chain reaction(qRT-PCR),and Western blot analysis.Results In the in vitro study,the CCK-8 assay demonstrated that FZJG at concentrations ≤ 40 000 μg/mL maintained cell viability above 95%.Based on safety and efficacy considerations,10 000 μg/mL was selected as the optimal concentration for subsequent experiments.FZJG significantly reduced intracellular ROS production in LPS-stimulated H9c2 cells,downregulated the mRNA expression of IL-6,IL-1β,TNF-α,Bax,and Caspase-3,and upregulated Bel-2 mRNA expression.These protective effects were further enhanced by co-treatment with SB203580(all P<0.05).In the in vivo study,medium-and high-dose FZJG significantly reduced serum levels of creatine kinase-MB(CK-MB),lactate dehydrogenase(LDH),and cardiac tropo-nin I(cTnI),alleviated myocardial histopathological injury,suppressed inflammatory cytokine expression,improved oxi-dative stress status by increasing superoxide dismutase(SOD)and glutathione(GSH)while reducing malondialdehyde(MDA),inhibited cardiomyocyte apoptosis,and decreased myocardial p38MAPK mRNA expression and protein phosphoryl-ation levels(all P<0.05).Combined treatment with SB203580 produced synergistic cardioprotective effects.Conclusion Fuzheng Jiedu Granules exert significant protective effects against sepsis-induced myocardial injury.The underlying mecha-nism may involve inhibition of p38MAPK signaling pathway activation,thereby attenuating inflammatory responses,oxidative stress,and cardiomyocyte apoptosis.These findings provide experimental evidence supporting the development of FZJG as a multi-target traditional Chinese medicine formulation for the treatment of sepsis-induced cardiomyopathy.

李瑞琳;张航;水敬伟;郭权来;赖芳;陈映红;王进忠

广州中医药大学第二临床医学院(广东 广州 511400)广州中医药大学第二临床医学院(广东 广州 511400)广州中医药大学第二附属医院、广东省中医院、广东省中医药科学院急诊科(广东 广州 510120)广州中医药大学第二附属医院、广东省中医院、广东省中医药科学院急诊科(广东 广州 510120)广州中医药大学第二附属医院、广东省中医院、广东省中医药科学院重症医学科(广东 广州 510120)广州中医药大学第二临床医学院(广东 广州 511400)广州中医药大学第二附属医院、广东省中医院、广东省中医药科学院急诊科(广东 广州 510120)

医药卫生

脓毒症心肌损伤扶正解毒颗粒p38MAPK信号通路机制研究

sepsismyocardial injuryFuzheng Jiedu Granulesp38MAPK signaling pathwaymechanism study

《广东医学》 2026 (7)

1030-1040,11

省部共建中医湿证国家重点实验室项目(SZ2022XG03)广州市科技局市院联合资助项目(2023A03J0229)广东省中医院谭燮尧、张浣天名中医学术经验传承工作室项目(E48807)

10.13820/j.cnki.gdyx.20260581

评论